OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
15 September 2023 - 1:00PM
OKYO Pharma Announces Closing of $4.0 Million Registered Direct
Offering of Ordinary Shares
OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease (“DED”), today announced
the closing of its previously announced Company best efforts
registered direct offering of 2,666,670 ordinary shares at an
offering price of $1.50 per ordinary share conducted
without an underwriter or placement agent to individuals and
institutions. The gross proceeds to OKYO from the offering, before
deducting estimated offering expenses payable by OKYO,
were $4.0 million.
OKYO intends to use the net proceeds from the
offering primarily for clinical development of the Company’s
product candidates, general corporate purposes and working
capital.
The securities described above are being offered
and sold pursuant to a shelf registration statement on Form F-3
(File No. 333-272516), including a base prospectus, filed with the
U.S. Securities and Exchange Commission (the “SEC”) on June 8,
2023, and declared effective on June 14, 2023. The offering is
being made only by means of a prospectus supplement and the
accompanying base prospectus, as may be further supplemented by any
free writing prospectus and/or pricing supplement that the Company
may file with the SEC. The final prospectus supplement related to
the offering has been filed with the SEC and is available on the
SEC website.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction.
About OKYO PharmaOKYO Pharma
Limited (Nasdaq: OKYO) is a life sciences company, focusing on the
discovery and development of novel molecules to treat inflammatory
dry eye diseases and chronic pain.
Forward-Looking
StatementsStatements in this press release may be
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that concern matters
that involve risks and uncertainties that could cause actual
results to differ materially from those anticipated or projected in
the forward-looking statements. These forward-looking statements
are not historical facts but rather are based on the Company's
current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
reflect the current beliefs and expectations of management and
include statements regarding the closing of the offering and the
registered direct offering. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement.
Forward-looking statements are subject to risks and uncertainties
that may cause the Company’s actual activities or results to differ
materially from those indicated or implied by any forward-looking
statement, including, without limitation, due to risks disclosed in
the section titled "Risk Factors" included in the final prospectus
supplement filed with the SEC, and risks disclosed in other
documents OKYO files from time to time with the SEC. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
+44 (0)20 7495 2379 |
|
|
|
Investor
Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024